509 A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer

by Evan Hall, Carlo Bifulco, Aung Naing, Anthony Joshua, Georgina Long, Margaret Callahan, Brian Costello, Aaron Hansen, Brooke Shankles, Umut Ulge, Andrew Weickhardt
Published 2021-11-01

717 A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: interim results from dose escalat...

by Andrew Haydon, John Powderly, Timothy Wyant, James Vasselli, Drew Rasco, Meredith McKean, Elizabeth Ahern, Sophia Frentzas, Andrew Weickhardt, Inbar Amit, Aron Knickerbocker, Yanay Ofran, Paul de Souza, Jenny Tang, Lori Richards
Published 2023-11-01

Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer

by Angelyn Anton, Sruti Pillai, Marie Christine Semira, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun Azad, Edmond M. Kwan, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Olivia Baenziger, Peter Gibbs, Ben Tran
Published 2022-05-01

Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial

by Samuel Tremblay, Mofarej Alhogbani, Andrew Weickhardt, Ian D Davis, Andrew M Scott, Rodney J Hicks, Ur Metser, Sue Chua, Reena Davda, Shonit Punwani, Heather Payne, Nina Tunariu, Bao Ho, Sympascho Young, Mahukpe Narcisse Ulrich Singbo, Glenn Bauman, Louise Emmett, Frédéric Pouliot
Published 2023-06-01

A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

by Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S. Hong, Lillian L. Siu, Miguel Martin, Michela Maur, Rina Hui, Ross A Soo, Joanne Chiu, Tian Zhang, Brigette Ma, Chrisann Kyi, Daniel SW Tan, Philippe A. Cassier, John Sarantopoulos, Andrew Weickhardt, Richard D. Carvajal, Jennifer Spratlin, Taito Esaki, Fréderic Rolland, Wallace Akerley, Barbara Deschler-Baier, Lawrence Rispoli, Tanay S. Samant, Niladri Roy Chowdhury, Daniel Gusenleitner, Eunice L. Kwak, Vasileios Askoxylakis, Filippo De Braud
Published 2024-12-01

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

by Xiaoyu Zhang, Anthony M Joshua, Sanjeev Kaul, Scott Antonia, Robert L Ferris, Roger B Cohen, Ezio Bonvini, Jan Baughman, Victoria Atkinson, Charu Aggarwal, Nicholas Vogelzang, Osama Rahma, Mahesh Seetharam, Yanyan Lou, Anthony Tolcher, Fernanda I Arnaldez, Amy Prawira, Ralph Hauke, Vinod Ganju, Andrew Weickhardt, Dan P Zandberg, Arash Rezazadeh Kalebasty, Alex A Adjei, Ariel Birnbaum, Rosetta Cavallo, Linda Peng, Paul A Moore, Stacie M Goldberg, Nehal J Lakhani
Published 2022-04-01

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

by Tian Zhang, Filippo de Braud, Taito Esaki, Wallace Akerley, Chrisann Kyi, Richard D Carvajal, Daniel Gusenleitner, Patrick Schöffski, Miguel Martin, David S Hong, Amy Prawira, Jürgen Krauß, Nidhi Patel, Rina Hui, Andrew Weickhardt, Niladri Roy Chowdhury, Daniel S W Tan, María Ochoa-de-Olza, John Sarantopoulos, Ross A Soo, Michela Maur, Barbara Deschler-Baier, Allen Lau, Tanay S Samant, Tyler Longmire, Catherine A Sabatos-Peyton, Radha Ramesh, Tiancen Hu, Ana Carion, Padmaja Yerramilli-Rao, Vasileios Askoxylakis, Eunice L Kwak
Published 2022-02-01